Clinical Trial

With major clinical trials progressing and a $110M war chest, Orchestra BioMed is orchestrating a potential shift in cardiovascular treatment.

With its pivotal trial fully enrolled, AQUAPASS's skin-based therapy could soon offer a kidney-independent alternative to millions with heart failure.

A new drug, divesiran, shows stunning success in trials, offering hope to those with a rare blood cancer by potentially replacing frequent phlebotomies with a quarterly shot.

A landmark clinical trial for Progressive Supranuclear Palsy has begun. We deconstruct the novel platform design that offers new hope against a devastating disease.

For a rare brain disease with no cure, a revolutionary trial design offers a faster path to treatment and renewed hope for thousands of patients and families.

With its Duchenne therapy nearing a pivotal FDA meeting, Solid Biosciences isn't just developing a drug; it's building a network for genetic repair.

With $911M in the bank, Relay Therapeutics is aggressively advancing its precision drug zovegalisib, targeting both breast cancer and rare vascular anomalies.

Zentalis Pharmaceuticals is pursuing a dual strategy for its ovarian cancer drug, azenosertib, aiming for fast market entry while securing long-term validation.

With a $215M war chest and a runway into 2028, Corvus Pharmaceuticals is aggressively advancing its lead drug, soquelitinib, across cancer and immune diseases.

A landmark study on equicenta® CTM shows it nearly triples a horse's odds of returning to performance, offering a ready-to-use solution that challenges the status quo.

Biotech firm MetaVia reports progress on its obesity drug DA-1726, with patients reaching high doses. Promising early data sets the stage for a pivotal Q4 readout.

Vexev’s AI-powered robotic ultrasound platform just raised $6M to tackle the specialist shortage and transform cardiovascular disease diagnostics for millions.

With 26 successful procedures, ForSight Robotics proves its JASPER platform can master cataract surgery, paving the way for AI in the operating room.

Beyond the clinical data, ALX Oncology's latest update reveals a masterclass in strategic finance and leadership, positioning it for critical milestones.

A new clinical trial is testing a novel oncolytic virus, VCN-01, to break down pancreatic cancer's defenses, a key step toward a pivotal therapy.

Facing Nasdaq pressure, Barinthus Bio advances its Clywedog merger and pivotal celiac disease trial, with key data expected in Q4 2026.

A critical safety milestone for PepGen’s PGN-EDODM1 offers a glimmer of hope for myotonic dystrophy patients and highlights a novel strategy in a competitive field.

Acrivon's ACR-2316 shows durable responses in lung cancer, moving to the next phase. The trial's design, guided by AI, aligns with new FDA standards.

A revenue dip masks a calculated pivot. UTHR is betting its future not just on new drugs, but on a revolutionary plan to manufacture human organs.

Entropy Neurodynamics launches a world-first 'basket study' for its IV psilocin, a high-stakes bet that could redefine mental health treatment pipelines.